Full name
"NOVO NORDISK PHARMA" SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
uses securityreCAPTCHA
"NOVO NORDISK PHARMA" SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
UL. KRAKOWIAKÓW 46, 02-255 WARSZAWA
TAX ID5271113612
Rate company:
"NOVO NORDISK PHARMA" SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
TAX ID5271113612
KRS0000092404
Share capital9,021,000.00 zł
address
UL. KRAKOWIAKÓW 46, 02-255 WARSZAWA
Categories
Main category
Is this your company?Update company information to get new customers, get notified of new reviews, and more!
Register Data
NIP
5271113612
REGON
011901401
KRS
0000092404
Legal form
limited liability company
Register Address
UL. KRAKOWIAKÓW 46, 02-255 WARSZAWA
Date of registration in KRS
2002-02-18
Date of commencement of economic activity
2002-02-18
Act signature
WA.XIV NS-REJ.KRS/16848/25/750
Pkd codes
72.11.Z - Scientific research and development activities
46.46.Z - Wholesale trade of pharmaceutical and medical products
46.75.Z - Wholesale trade
47.73.Z - Retail sale of pharmaceutical products
71.20.B - Inspection and issuing opinions on the technical condition of chimneys and ventilation ducts
72.19.Z - Scientific research and development activities
73.12.B - Advertising through mass media
73.12.D - Advertising through mass media
82.30.Z - Activities related to organizing fairs, exhibitions, and congresses
85.59.B - Courses and training for acquiring knowledge, skills, and professional qualifications in non-school forms
Payer VAT status
Active
Vat list bank account(s)
PL73 1050 0086 1000 0090 3050 2950 
Financial data
Net sales [PLN]
Gross profit / loss [PLN]
Automatically generated based on financial statements from KRS Registry
| 2021 | 2022 | 2023 | ||
|---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss)  | 11,2 | 13,8 | 20,3 | 47,3 |
EBITDA | 12,2 | 14,7 | 20,7 | 40,1 |
Short time liabilities | 36,9 | 46,4 | 63,5 | 36,9 |
Equity capital | 31,8 | 41,5 | 56,4 | 35,9 |
Operating profit (EBIT) | 11,8 | 14,3 | 20,2 | 41,3 |
Assets | 79,9 | 102,2 | 150,6 | 47,4 |
Net profit (loss) | 11,9 | 9,7 | 14,9 | 54,1 |
Cash | 7,8 | 1,1 | 8,9 | 730,1 |
Net income from sale | 169,1 | 234,2 | 327,1 | 39,7 |
Liabilities and provisions for liabilities | 48,1 | 60,7 | 94,2 | 55,3 |
Working assets | 71,4 | 93,1 | 136,4 | 46,5 |
Depreciation | 0,4 | 0,4 | 0,5 | 3,3 |
% | % | % | p.p. | |
Profitability of capital | 37,3 | 23,3 | 26,4 | 3,1 |
Equity capital to total assets | 39,8 | 40,6 | 37,4 | -3,2 |
Gross profit margin | 6,6 | 5,9 | 6,2 | 0,3 |
EBITDA Margin | 7,2 | 6,3 | 6,3 | 0 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 80 | 72 | 71 | -1 |
Current financial liquidity indicator | 1.5916368961334229 | 1.609873652458191 | 1.5807162523269653 | 0 |
Net dept to EBITDA | -0.634123682975769 | 0.08203549683094025 | -0.4310552179813385 | -0,5 |
Financial statements
01-01-2023 - 31-12-2023
Resolution or decision approving the annual financial statements
Download pdf01-01-2023 - 31-12-2023
Resolution on profit distribution or loss coverage
Download pdf01-01-2023 - 31-12-2023
Activity report
Download pdf01-01-2023 - 31-12-2023
Annual financial report
Download xml01-01-2023 - 31-12-2023
Annual financial report
Download pdf01-01-2023 - 31-12-2023
Auditor's opinion / report on the audit of the annual financial statements
Download pdfShow more (3)
uses security reCAPTCHA
Opinions
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane
0/ 5.0
How do you rate this company?
Your opinion matters to us.
Companies registered in the same sector
Emprime sp. z o.o.
Sękocin Nowy
Bardomed sp. z o.o.
Kraków
CYTOGEN-POLSKA
ŁÓDŹ
VITAMIN CLINIC WROCŁAW
Wrocław
UROMED POLAND
TORUŃ
KGU Konsult Wojciech Guzowski
Warszawa
"SOLINEA" sp. z o.o. sp.k.
Ciecierzyn
Katarzyna Poleszak
Toruń